Figure 1.
Proportion of patients in the primary cohort who initiated T-DM1 following treatment with pertuzumab by calendar year. The primary cohort comprised patients who received T-DM1 in any treatment line. T-DM1 = trastuzumab emtansine.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.